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Common SNPs in the chromosome 17q12-q21 region alter the risk for asthma, type 1 diabetes, primary biliary cirrhosis, and Crohn
disease. Previous reports by us and others have linked the disease-associated genetic variants with changes in expression of GSDMB
and ORMDL3 transcripts in human lymphoblastoid cell lines (LCLs). The variants also alter regulation of other transcripts, and this
domain-wide cis-regulatory effect suggests a mechanism involving long-range chromatin interactions. Here, we further dissect the
disease-linked haplotype and identify putative causal DNA variants via a combination of genetic and functional analyses. First, high-
throughput resequencing of the region and genotyping of potential candidate variants were performed. Next, additional mapping of
allelic expression differences in Yoruba HapMap LCLs allowed us to ﬁne-map the basis of the cis-regulatory differences to a handful
of candidate functional variants. Functional assays identiﬁed allele-speciﬁc differences in nucleosome distribution, an allele-speciﬁc
association with the insulator protein CTCF, as well as a weak promoter activity for rs12936231. Overall, this study shows a common
disease allele linked to changes in CTCF binding and nucleosome occupancy leading to altered domain-wide cis-regulation. Finally,
a strong association between asthma and cis-regulatory haplotypes was observed in three independent family-based cohorts
(p ¼ 1.78 3 108). This study demonstrates the requirement of multiple parallel allele-speciﬁc tools for the investigation of noncoding
disease variants and functional ﬁne-mapping of human disease-associated haplotypes.Introduction
Bronchial asthma (MIM 600807) is the most common
chronic disease among children and young adults1 and is
characterized by intermittent inﬂammation of the small
airways of the lung with characteristic symptoms of
wheezing and shortness of breath. Asthma and asthma-
related traits are complex genetic disorders because of the
interactions between multiple genes and environmental
factors.2 To date, more than 30 replicated loci have been
associated with these diseases.3 A genome-wide association
study (GWAS) reported common SNPs in the 17q12-q21
region to be associated with childhood asthma and also
linked with the expression level of the ORM1-like 3 (S. cer-
evisiae) (ORMDL3) gene4 (MIM 611403). Furthermore, one
SNP (rs7216389) based on evolutionary conservation was
highlighted as the potential causal variant. To date, several
other studies have replicated this association for adult
asthma in different ethnic groups.5–8 The rs7216389 SNP
is found within a large CEU (CEPH collection of individ-
uals of European descent) linkage disequilibrium (LD)
block that encompasses not onlyORMDL3, but also gasder-The Americanmin B (GSDMB), zona pellucida binding protein 2 (ZPBP2),
and IKAROS family zinc ﬁnger 3 (Aiolos) (IKZF3) genes
(Figure 1). Another variant (rs2872507) located within
this same LD block has been associated with Crohn disease
(CD)9 (IBD22, MIM 612380). More recently, the same
region was associated with the risk of type 1 diabetes
(T1D) (MIM 222100)10 and primary biliary cirrhosis
(PBC) (MIM 109720).11 Therefore, elucidation of the
genetic mechanisms of transcriptional control of the
IKZF3-ORMDL3 genomic regionmay potentially shed light
on the pathogenesis of multiple complex diseases.
To validate and map regulatory variants affecting gene
regulation, measurement of allelic expression (AE) differ-
ences in individuals provides a speciﬁc means to assess
cis-acting variation. We have recently developed a highly
sensitive approach for mapping cis-regulatory variation
based on interindividual variation in AE (B.G., D.K. Pokho-
lok, T.K., E.G., L. Morcos, D.J.V., J. Le, V.K., K.C.L.L.,
V. Gagne´, J.D., R.H., A. Montpetit, M.-M. Joly, E.J. Harvey,
D.S., P. Beaulieu, R. Hamon, A. Graziani, K.D., E.H., J.
Majewski, H.H.H. Go¨ring, A.K.N., M. Blanchette, K.L. Gun-
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Figure 1. Allelic Expression Analysis of the Genes Found in the Vicinity of rs7216389
(A) RefSeq genes found within the 17q12-q21 region.
(B) Informative windows tested for AE via the Illumina 1M duo (three intergenic [] regions with expressed SNPs were also tested [in
gray]).
(C) Location of pertinent SNPs.
(D) Blocks showing the top association for each transcript (log10(p value)) via high-throughput AE mapping data generated from 34
informative CEU HapMap LCLs by the Illumina 1M BeadChips (B.G., D.K. Pokholok, T.K., E.G., L. Morcos, D.J.V., J. Le, V.K., K.C.L.L., V.
Gagne´, J.D., R.H., A. Montpetit, M.-M. Joly, E.J. Harvey, D.S., P. Beaulieu, R. Hamon, A. Graziani, K.D., E.H., J. Majewski, H.H.H. Go¨ring,
A.K.N., M. Blanchette, K.L. Gunderson, and T.P., unpublished data).
(E and F) GSDMB AE mapping results for 32 informative CEU LCLs (E) (stars delimit the 160 kb CEU rHAP) and for 21 informative YRI
LCLs (F) (stars delimit the 22 kb YRI rHAP). Vertical red lines correspond tolog10(p value) of the AE assay for each SNP tested and gener-
ated by a two-sided Fisher’s exact test.
(G and H) Linkage disequilibrium (r2) for CEU phased genotype data (G) and for YRI phased genotype data (H).cis-regulatory components ofAEallowsus to identify strong
genetic inﬂuences on the allelic transcriptional regulation
of genes. Earlier AE and cis-eQTL studies on the HapMap
CEU lymphoblastoid cell lines (LCL) by us and others
(Ge et al. unpublished data12,13) as well as in other CEU
LCLs14 have revealed that asthma-associated SNPs modify
the expression levels of ORMDL3 and GSDMB. Originally,
the expression change of ORMDL34 was put forward as
a functional mechanism underlying the asthma associa-
tion; however, the fact that more than one transcript is
under genetic control in this region suggests that themech-
anism may be more complex.
In this study, we undertook several steps to identify the
SNPs involved in the observed AE. First, to identify all the378 The American Journal of Human Genetics 85, 377–393, Septempotential DNA variants that may affect AE, we resequenced
the 160 kb AE-associated CEU haplotype. Next, we reﬁned
this AE-associated haplotype by measuring AE in a second
population of LCLs (Yoruba [YRI]) and generated a map of
SNPs associated with AE. The domain-wide inﬂuence of
the haplotype on the expression of the 17q12-q21 genes
was suggestive of long-range chromatin effects. Therefore,
to identify DNA polymorphisms associated with allele-
speciﬁc chromatin effects, we screened candidate SNPs
via formaldehyde-assisted isolation of regulatory elements
(FAIRE). We identiﬁed one SNP that demonstrated stable
allelic differences in association with nucleosomes and
the insulator protein CTCF. Parallel analysis of our three
best candidate SNPs via EMSA across multiple cell typesber 11, 2009
revealed a second functional SNP in the same haplotype.
Finally, we show the close link between the identiﬁed func-
tional variants and asthma risk in several asthma cohorts.
Material and Methods
Cell Culture of Lymphoblastoid Cell Lines
HapMap immortalized lymphoblastoid cell lines (LCLs) were
grown in T75 ﬂasks in 1X RPMI 1640 Media (Invitrogen, Burling-
ton, ON) (with 2 mM L-glutamine, 15% fetal bovine serum, and
1% penicillin/streptomycin) at 37C with 5% CO2. For the FAIRE,
MNase treatment, N-ChIP and X-ChIP assays, LCLs were grown to
90% conﬂuency. Two independent cultures of cells were used for
the FAIRE assay (input and FAIRE-treated cells). The study was
approved by the local ethics committee (McGill University IRB).
RNA Extraction and Reverse Transcription
for Expression Analysis
Total RNA was extracted from cell lysates of 53 and 57 unrelated
CEU and YRI HapMap LCLs,15 respectively, with the RNeasy Mini
Kit (QIAGEN, Mississauga, ON). High-quality RNA was conﬁrmed
for all samples with an Agilent 2100 BioAnalyzer (Agilent Technol-
ogies, PaloAlto, CA), and the concentrationswere determinedwith
the Nanodrop ND-1000 (NanoDrop Technologies, Wilmington,
DE). Total RNAwas annealed to 250 ng of random hexamers (Invi-
trogen, Carlsbad, CA) at 70C for 10 min. First-strand cDNA
synthesis was performed with SuperScript II reverse transcriptase
(Invitrogen) according to the manufacturer’s instructions. The
CEU cDNA was used for gene expression analysis of the 17q12-
q21 region by quantitative real-time PCR whereas the YRI cDNA
was used for AE measurements of GSDMB and ORMDL3.
DNA Isolation
Genomic DNA (gDNA) from the CEU and YRI cell lysates was
extracted with the GenElute DNA Miniprep Kit (SigmaAldrich,
Oakville, ON) according to the protocol provided by the manufac-
turer, and concentrations were determined with the Nanodrop
ND-1000.
Primer Design
All primers were designed with the Primer3 v. 0.4.0 software.
Primer sequences can be found in Table S1 available online.
Allelic Expression Measurements and Mapping by
Normalized Sanger Sequencing in CEU and YRI LCLs
AE measurements for GSDMB and ORMDL3 in the CEU LCLs have
been previously reported12 and were generated by normalized
Sanger sequencingwith thePeakPicker software,16whichcompares
cDNA sequence allele ratios to the gDNA allele ratio and accounts
for reaction-to-reaction variation in nucleotide incorporation
(causing technical variation in heterozygote ratios) by normalizing
allele ratios to ﬂanking sequence allele-speciﬁc ﬂuorescence. AE
measurements by normalized Sanger sequencing in the YRI
LCLs were assayed with intragenic SNPs in individuals that were
heterozygous for that SNP. GSDMB was assayed with rs1008723,
rs7216389, and rs7219923 whereas ORMDL3 was assayed with
rs12603332 and rs8076131. In brief, the gDNA and cDNA from
heterozygous samples was ampliﬁed for each marker SNP in
duplicate, veriﬁed by agarose gel electrophoresis, and sequenced
with ABI Big Dye chemistry and capillary electrophoresis on anThe AmericanABI 3730 sequencer (Applied Biosystems, Foster City, CA). Relative
allelic expression levels for each SNP were assessed with the Peak-
Picker software.12,16
To determine which SNPs were associated with AE, the popula-
tion distribution of AE in phased chromosomes was tested for
association with a two-sided Fisher’s exact test.17,18 To assess the
signiﬁcance level of the Fisher’s exact tests, permutation tests
were performed by shufﬂing the AE phenotypes among the infor-
mative LCL samples (n ¼ 100,000), repeating the Fisher’s exact
tests for all ﬂanking SNPs and keepingminimump values achieved
in each permutation cycle to derive empirical, locus-wide signiﬁ-
cance. Phased haplotype and AE phenotype information for
each HapMap LCL used as well as Fisher’s exact test p values for
each SNP can be found in Table S2 (GSDMB [CEU]), Table S3
(ORMLD3 [CEU]), Table S4 (GSDMB [YRI]), and Table S5 (ORMDL3
[YRI]).
Genome-wide Allelic Expression Measurements
in CEU LCLs
Genome-wide AE measurements in 53 CEU LCLs and data from
CEPH family 1420 was generated on the Illumina 1M BeadChips
(B.G., D.K. Pokholok, T.K., E.G., L. Morcos, D.J.V., J. Le, V.K.,
K.C.L.L., V. Gagne´, J.D., R.H., A. Montpetit, M.-M. Joly, E.J. Harvey,
D.S., P. Beaulieu, R. Hamon, A. Graziani, K.D., E.H., J. Majewski,
H.H.H. Go¨ring, A.K.N., M. Blanchette, K.L. Gunderson, and T.P.,
unpublished data). In brief, D heterozygote ratios (D het ratios ¼
het ratio in gDNA – het ratio in cDNA) in expressed SNPs were
calculated for each transcript in the chromosome 17 region and
the average D het ratios for any transcript with more than two
expressed SNP in an individual were derived from phased chromo-
somes. The median D het ratios were converted to estimated fold-
differences (Figure 2; Figure S1) via the formula (0.5þ D het ratio)/
(0.5 D het ratio). A regression-based statistic was used tomap the
AE phenotypes of the CEU LCLs to local SNPs (Figure 1D). Tran-
scripts were considered to harbor common cis-variants if they
could be signiﬁcantly mapped to SNPs. Multiple testing in AE
regression test for each locus was corrected for by requiring empir-
ical (based on 10,000 permutations) signiﬁcance of 0.005 or lower.
Resequencing of the CEU Haplotype and Genotyping
of Non-HapMap SNPs
To identify all genetic polymorphisms potentially responsible for
the differences in allelic expression, the large CEU LD block
(hg18, chr17:35179985-35339296) was resequenced with tiled
long-range PCRs coupled with 454 GS-FLX sequencing (Roche,
Quebec, Canada) in four individuals heterozygous for the overex-
pressed-associated haplotype (CEU, NA07056 and NA07345; YRI,
NA18871 and NA18858) and demonstrating AE. Non-HapMap
SNPs that were heterozygous in at least two of the four samples
were determined by a novel SNP-calling algorithm (ProbHD).19
ProbHD provides a heterozygosity probability for each chromo-
somal position and allows the identiﬁcation of preferentially
ampliﬁed fragments and other poorly sequenced regions. In indi-
vidual samples andwith an average fold-coverage of 203–503, the
de novo heterozygote detection has 5%–10% false-call rate and
~90% sensitivity, but adding information across four samples
allows for detection of shared heterozygous sites at 95% sensitivity
with lower than 5% false call rate.19 Newly identiﬁed non-Hap-
Map SNPs were genotyped in our panel of 30 CEU and 30 YRI
HapMap trios15 with the Sequenom MassARRAY iPLEX Gold
(Sequenom Inc., Newton, MA). If the Sequenom assay failed, theJournal of Human Genetics 85, 377–393, September 11, 2009 379
Figure 2. Transmission of AE Observed
for GSDMB in the LCLs from CEPH Family
1420
Relative underexpression () or overex-
pression (þ) is shown below the family
member when data were available. The
estimated fold differences between alleles,
measured with the Illumina 1M BeadChip
AE analysis (B.G., D.K. Pokholok, T.K.,
E.G., L. Morcos, D.J.V., J. Le, V.K., K.C.L.L.,
V. Gagne´, J.D., R.H., A. Montpetit, M.-M.
Joly, E.J. Harvey, D.S., P. Beaulieu, R. Ha-
mon, A. Graziani, K.D., E.H., J. Majewski,
H.H.H. Go¨ring, A.K.N., M. Blanchette, K.L.
Gunderson, and T.P., unpublished data), is
shown in the bar graph for each family
member. The red color represents the
haplotype associated with underexpres-
sion of GSDMB (rs12936231>G) while the
blue color represents the overexpressed-
associatedhaplotype (rs12936231>C). The
expression differences between the alleles
are subtle, but are reproducible and corre-
late perfectly with what is expected based
on population AE mapping.SNPs were genotyped by standard Sanger sequencing but only in
the YRI panel. In total, 13 variants discovered in sequencing
were tested (Table S7). All strong candidates (heterozygous in all
four individuals included in large-scale sequencing) were among
successfully genotyped sites (n ¼ 10, 3 SNPs located in SINE
repeats could not be typed by Sequenom or Sanger sequencing).
Finally, the 160 kb region was also examined for potential inser-
tions, deletions, and copy number variations with the Database
of Genomic Variants.20
Expression Analysis by Quantitative Real-Time PCR
To evaluate the impact of the CEU AE-associated haplotype on the
gene expression of IKZF3, ZPBP2,GSDMB, andORMDL3, quantita-
tive real-time PCR on a panel of 53 CEU LCLs was performed. PCR
products from each pair of primers (Table S1) were tested by
agarose gel electrophoresis to verify the presence of a single
band of the predicted size. First-strand cDNA ampliﬁcation was
performed with the Applied Biosystems (ABI 7900HT) real-time
PCR machine with the GeneAmp 7900HT sequence detection
system software (PerkinElmer Corp., Foster City, CA), and the
detection was made by measuring the binding of the ﬂuorescence
dye SYBR Green I to double-stranded DNA. PCR reactions were set
up in 384-well plates in 10 ml volumes comprising 2 ml cDNA,
7.936 ml of Power SYBRGreen PCRmaster mix 23 (Applied Biosys-
tems), and 0.32 mM of gene-speciﬁc primers. The program was as
follows: an initial step at 95C (10 min) and then 40 cycles of
95C (20 s), 58C/60C (30 s), and 72C (45 s). The results were
analyzed with the relative standard curve method. The mean
and SD values for the technical triplicates were calculated, and
the mean value was then normalized to the ribosomal protein
18S housekeeping gene (RPS18) mean to obtain the target-to-
reference ratio. Linear regression analysis was performed with
R, v2.8.0.21
Formaldehyde-Assisted Isolation of Regulatory
Elements Assay
The formaldehyde-assisted isolation of regulatory elements
(FAIRE) procedure was performed as described22 with some modi-380 The American Journal of Human Genetics 85, 377–393, Septemﬁcations. In brief, cells were ﬁxed for 7min with 1% formaldehyde
and incubated for 5 min with 125mM glycine. The cells were then
collected at 2000 rpm (4 min, 4C) and washed 3 times with
13 phosphate-buffered saline (PBS) containing 0.2 mM phenyl-
methylsulphonylﬂuoride (PMSF, EM). Cells were snap frozen in
liquid nitrogen and stored at 80C. The frozen cells were resus-
pended in lysis buffer containing protease inhibitors (1 mg/ml leu-
peptin, 1 mg/ml pepstatin, 2 mg/ml aprotinin, 0.2 mM PMSF) and
homogenized. Samples were sonicated for 3 sessions of 30 pulses
(1 s on/1 s off) with a Branson DIGITAL Soniﬁer UNITS (Models
S-450D) at 15% amplitude to have a DNA fragment distribution
between 1 kb and 300 bp. After removing cellular debris by centri-
fugation, a phenol-chloroform extraction was performed to
recover the DNA. The DNAwas quantiﬁed by a spectrophotometer
and stored at 20C.
To test for FAIRE enrichment of speciﬁc SNP regions, 200 to
500 ng of DNA was ampliﬁed by PCR. For each SNP, at least two
heterozygous LCLs were tested. For SNP regions that showed
FAIRE enrichment, normalized Sanger sequencing was done.
FAIRE-treated DNA samples were compared to the input DNA
samples and normalized allelic ratios were calculated.
MNAse Treatment
The nuclei from LCLs were prepared as described.23 A total of
2530 3 106 nuclei were incubated with 10 U of MNase (Fermen-
tas, Burlington, ON) for 10 min at 37C. Digestion was stopped
with 20 mM EDTA (pH 8.0). Chromatin fractions containing
mononucleosomes and oligonucleosomes were puriﬁed, PCR
ampliﬁed, and sequenced. Primers are shown in Table S1.
Native Chromatin Immunoprecipitation
Native chromatin fragments were prepared from fresh cell culture
as described23 with somemodiﬁcations. The nuclei were incubated
in a dialysis buffer for 1 hr at 4Con a rotatingwheel. 30 mg of chro-
matinwas incubatedwith10 mgof commercial antibodies and then
with 50 ml protein-G sepharose (GE Healthcare, Uppsala, Sweden)
and washed. The DNA was puriﬁed and analyzed by quantitative
PCR with a Rotor-Gene 6000 (Corbett Life Science, Montreal,ber 11, 2009
QC). Speciﬁc antibodies for acetylated histone H3 (H3Ac), histone
H3 methylated at lysine 9 (H3K9me3), and histone H4 trimethy-
latedon lysine27 (H3K27me3)werepurchased fromUpstate (Milli-
pore, Temecula, CA).
Crosslinking Chromatin Immunoprecipitation Assay
Fresh LCL cultures were used. Formaldehyde (37% formaldehyde,
11% methanol, Fisher) was added directly to the ﬂask (containing
40–503 106 cells) to a ﬁnal concentration of 1% and incubated for
10 min at room temperature without shaking. To quench the
formaldehyde, 125 mM of glycine was added to the ﬁxed cells.
Cells were collected at 1500 rpm for 4 min (4C) and washed
3 times with 13 PBS containing protease inhibitors and sodium
butyrate. Chromatin immunoprecipitations were performed as
previously described24 with some modiﬁcations. Immunoprecipi-
tation buffer contained 3 mM EDTA and 25 mM Tris-HCl (pH 8.0).
Cells were sonicated for 3 sessions of 30 pulses (1 s on/1 s off) with
Branson Soniﬁer at 15% amplitude. Cell debris was removed by
centrifugation and aliquots of the supernatant were taken for
quantiﬁcation and veriﬁcation of proper sonication while the re-
maining was stored at 80C until use.
25 mg of chromatin was precleared with 50 ml of protein G
sepharose (GE Healthcare, Uppsala, Sweden) and then incubated
overnight at 4Cwith 10 mg of commercial antibodies in immuno-
precipitation buffer containing salmon sperm DNA (1 mg/ml
ﬁnal) and BSA (0.5 mg/ml ﬁnal). 50 ml of protein G sepharose
was added and the incubation continued for 4 hr. The chromatin
complexes were sequentially washed in low salt, high salt, LiCl
salt, and TE buffers. The protein/DNA complex was eluted in an
SDS elution buffer (1% SDS, 50 mM Tris [pH 8.0], 10 mM EDTA).
The crosslink between protein and DNA was reversed by treating
the protein/DNA complex with Proteinase K. Finally, the DNA
was puriﬁed with phenol-chloroform extractions. Speciﬁc anti-
bodies for CTCF were purchased from Upstate (Millipore, Teme-
cula, CA).
FAIRE and ChIP qPCR
For the quantitative real-time PCR (qPCR) assays, 20 ng of FAIRE-
treated DNA, immunoprecipitated DNA, or input DNA were used.
The qPCR was performed with 0.1 mM primers (Table S1) and
13 Power SYBR green PCR master mix (Applied Biosystems) on
the Rotor-Gene 6000 (Corbett Life Science) machine. The program
used was: 95C for 10 min; 40 cycles of 95C for 20 s, 55C–60C
for 20–30 s; and 72C for 45 s, followed by a melting step from
65C to 95C. Results were analyzed with the relative standard
curve method with the Rotor-Gene 6000 series software.
Normalization of the rs12936231 FAIRE-enriched region was
performed against the promoter of ORMDL3, which is also highly
enriched in protein-free DNA and does not show a genotype effect
(Figure S5).
For the ChIP assays, a series of controls were used to conﬁrm
antibody speciﬁcity and allele-speciﬁc effects: the promoter
region of the imprinted small nuclear ribonucleoprotein polypep-
tide N (SNRPN) gene, which is known to carry parent-of-origin-
speciﬁc chromatin modiﬁcations, the active nestin (NES) gene,
and the inactive ribosomal protein large P1 (RPLP1) genes were
used as controls for histone H3 modiﬁcations (Figure S2). The
differentially methylated region of H19, known to bind CTCF,25
and the promoter region of SNRPN were used as controls for
CTCF binding ChIP assays. The results were normalized to the
input DNA.The AmericanIn Vitro Transient Transfection Assays
To test for allelic activity, haplotype-speciﬁc constructs for
rs12936231 (chr17:35282398-35282865), rs9303277 (chr17:
35229745-35230240), rs8067378 (chr17:35304625-35305060),
and rs7216389 (chr17:35323239-35324267) were subcloned into
a pGL3 vector containing a ﬁreﬂy luciferase reporter gene either
with or without an SV40 promoter (Promega) via a previously pub-
lished method.26 All constructs were tested in ﬁve different
human immortalized cell lines. The cervical cancer (HeLa), chorio-
carcinoma (Jeg3), hepatocellular liver carcinoma (HepG2), osteo-
sarcoma (MG-63), and T cell lymphoblast-like (Jurkat) cell lines
were transfected with lipofectamine 2000 according to the manu-
facturer’s instructions (Invitrogen). To control for transfection efﬁ-
ciency, themeasurement of the ﬁreﬂy luciferase was normalized to
the measurement of the Renilla luciferase. Experiments were per-
formed in quadruplicate, the activities of the two luciferases
were measured 24 hr after transfection, and allelic haplotypes
for each SNP were compared. Statistical signiﬁcance (p value)
was determined with an unpaired Student’s t test.
Electrophoretic Mobility Shift Assay
EMSAswere carried out to test for allele-speciﬁcDNA-protein inter-
actions on rs9303277, rs12936231, rs8067378, and rs7216389. For
each SNP, double-stranded oligonucleotide probes corresponding
to each allelic variant were radiolabeled and incubated in the
presence of HeLa, HepG2, Jeg3, MG-63, or LCL (GM12815) cell
nuclear extracts. In brief, protein was quantiﬁed with the Bradford
protein assay (BioRad). Nuclear extracts (10 mg) were incubated
with 35 fmol radiolabeled double-stranded DNA probes and
with a buffer containing 50 mM Tris-HCl (pH 7.5), 5 mM MgCl2,
2.5 mM EDTA, 2.5 mMDTT, 250 mMNaCl, 0.25 mg/ml poly (deox-
yinosinate-deoxycytidylate), and 20% glycerol in a total volume of
10 ml, for 20 min at room temperature. Complexes were separated
on a nondenaturing 6% polyacrylamide gel (acrylamide-bisacryla-
mide, 37.5:1) in 13 Tris-glycine-EDTA buffer (190 V at 4C). For
binding competition, the EMSA was performed in the presence of
a 50-fold molar excess of the unlabeled oligonucleotide probe,
the unlabeled corresponding mutant probe, or a nonspeciﬁc DNA
probe. Binding competitions were carried out by preincubating
nuclear extracts in binding buffer for 10 min at room temperature,
followed by a 20 min incubation at room temperature with a
radiolabeled double-stranded DNA probe.
Genetic Association Studies in Asthma
Genetic association testing was performed in three family-based
childhood asthma cohorts: The Childhood Asthma Management
Program (CAMP),27,28 the Genetic Epidemiology of Asthma in
Costa Rica cohort,29 and the Saguenay-Lac-Saint-Jean (SLSJ) asth-
matic familial collection. CAMP is a multicenter, randomized,
double-blind, placebo-controlled trial to investigate the long-
term effects of inhaled anti-inﬂammatory medication. Of the
1041 children randomized in the clinical trial, 968 children and
1518 of their parents contributed DNA samples as part of the
genetic ancillary study of CAMP. DNA was sufﬁcient for 503
probands and parents for 470 nuclear families of self-reported
non-Hispanic white ancestry studied previously.30 Asthma was
deﬁned by a doctor diagnosis in conjunction with objective
evidence of airway hyperresponsiveness as deﬁned by amethacho-
line PC20 of 12mg/dl or less, and at least one of the following for at
least 6 months in the year before recruitment: (1) asthma symp-
toms at least two times per week, (2) at least two uses per weekJournal of Human Genetics 85, 377–393, September 11, 2009 381
of an inhaled bronchodilator, or (3) daily asthma medication use.
The Costa Rica cohort consists of 412 parent-child trios recruited
through asthmatic children ages 6 to 14 years. Children were
included in the study if they had asthma (a physician’s diagnosis
of asthma and R2 respiratory symptoms or asthma attacks in
the previous year) and a high probability of having R6 great-
grandparents born in the Central Valley of Costa Rica.31 The
SLSJ asthmatic familial collection comprises 253 asthmatic
probands and their relatives for a total of 1275 subjects. A propor-
tion of 36.6% of relatives are affected by asthma. Participants were
deﬁned as having asthma if (1) they had a reported history of
asthma (validated by a physician), or (2) they showed asthma-
related symptoms and a positive PC20 (provocative concentration
causing a 20% drop in FEV1 [PC20] < 8 mg/ml
32) at the time of
recruitment. Approval was obtained from the Institutional Review
Boards of Brigham and Women’s Hospital (Boston, MA), the
Hospital Nacional de Nin˜os (San Jose´, Costa Rica), the Centre de
Sante´ et de Services Sociaux de Chicoutimi, and each of the
CAMP-participating institutions. Informed consent was obtained
from parents of participating children, and the child’s assent was
obtained prior to study enrollment.
SNP genotyping was performed with the MassArray IPlex Gold
genotyping platform (Sequenom Inc) or TaqMan SNP Genotyping
Assays (Applied Biosystems). Genotype data quality was assessed
by genotype completion rates, discordance in the duplicate geno-
typing, and evidence of Mendelian inconsistencies.33 Family-
based association tests (FBAT) with asthma affection status were
conducted with the transmission disequilibrium test34 as imple-
mented in Haploview or via the FBAT software (Version 1.7) under
an additive model with the empirical variance estimator ‘‘-e.’’35
The number of effective independent SNPs was evaluated and after
factoring in speciﬁc criteria (use of one phenotype, one genetic
model, and 1.67 effective SNPs), we ﬁxed the signiﬁcance
threshold at 0.030 to keep the type I error rate at a 5% level.36
Results
Allelic Expression Mapping in the Chromosome
17q12-q21 Region
To speciﬁcally interrogate the roleof cis-regulatoryvariation
across the chromosome 17 region, we carried out detailed
analysis of the genome-wide AE data generated by the Illu-
mina 1M BeadChip Array (B.G., D.K. Pokholok, T.K., E.G.,
L. Morcos, D.J.V., J. Le, V.K., K.C.L.L., V. Gagne´, J.D., R.H.,
A. Montpetit, M.-M. Joly, E.J. Harvey, D.S., P. Beaulieu, R.
Hamon,A.Graziani, K.D., E.H., J.Majewski,H.H.H.Go¨ring,
A.K.N., M. Blanchette, K.L. Gunderson, and T.P., unpub-
lished data) with theHapMapCEULCLs. The allelic expres-
sion signal was strong forGSDMB andwas observed in 31 of
32 heterozygous individuals, whereas ORMDL3 (AE in 22/
31) and the intergenic region downstream of GSDMB (AE
in 20/28) showed moderate allele-speciﬁc expression
(Figure 1D). The ZPBP2 gene also showed nominal AE
association but did not reach 0.005 permutations signiﬁ-
cance level used to account for multiple testing in the
previous genome-wide screen of AE (Figure 1D) (B.G., D.K.
Pokholok, T.K., E.G., L. Morcos, D.J.V., J. Le, V.K., K.C.L.L.,
V. Gagne´, J.D., R.H., A. Montpetit, M.-M. Joly, E.J. Harvey,
D.S., P. Beaulieu, R. Hamon, A. Graziani, K.D., E.H., J.382 The American Journal of Human Genetics 85, 377–393, SeptemMajewski, H.H.H. Go¨ring, A.K.N., M. Blanchette, K.L. Gun-
derson, and T.P., unpublished data). An individual assayed
at a heterozygous intragenic SNP may not show AE of the
gene tested if that individual ishomozygous at the causative
SNP or if other external factors are confounding the results.
Furthermore, all of these genes show Mendelian transmis-
sion of the AE phenotype (Figure 2; Figure S1). The other
genes (IKZF3, GSDMA, and PSMD3) and intergenic regions
did not show any common AE (Figure 1D). Of these, we
have previously validated the AE in ORMDL3 and GSDMB
via normalized Sanger sequencing in CEU LCL samples.12
From the 32 and 29 CEU LCLs that showed AE for GSDMB
andORMDL3, respectively,wegeneratedmapsof SNPs asso-
ciated with AE12 with the phased genotype information for
each HapMap sample (Figure 1E; Table S2 for GSDMB and
Table S3 for ORMLD3). We note that although each gene
has multiple isoforms, differential expression of transcript
isoforms was not detected in a previous study via the
Affymetrix exon array in the CEU HapMap population,37
suggesting a minimal impact of the different isoforms
on the AE signals observed. In addition, total transcript
levels based onmetaprobeset associations in theAffymetrix
exon array as well as arrays measuring gene expression
at different sites for the transcripts (U133 and Illumina)
show results concordant with our data for GSDMB and
ORMDL3 (B.G., D.K. Pokholok, T.K., E.G., L. Morcos,
D.J.V., J. Le, V.K., K.C.L.L., V. Gagne´, J.D., R.H., A. Montpe-
tit, M.-M. Joly, E.J. Harvey, D.S., P. Beaulieu, R. Hamon,
A. Graziani, K.D., E.H., J. Majewski, H.H.H. Go¨ring,
A.K.N., M. Blanchette, K.L. Gunderson, and T.P., unpub-
lished data).13,37 Furthermore, the AE measurements
primarily target nonspliced primary transcripts and their
results are supported by in-house qRT-PCR experiments
as well as independent expression array data targeting
measurement of transcript levels.4,13
Haplotype-based analysis of the GSDMB and ORMDL3
ﬁne-mapping data revealed a common haplotype associ-
ated with an increase in gene expression (Tables S2
and S3). This haplotype is delineated by rs907091 and
rs12603332 (stars in Figure 1E) and contains 15 SNPs that
are equally strongly associated with AE (p ¼ 1.09 3 1018)
(Table 1).
The strong LD among the common SNPs associated with
AE in the CEU did not allow further delineation of the
causal variant(s). Consequently, we tested GSDMB and
ORMDL3 for AE in a second LCL population, the YRI,15
because the large LD block observed in the CEU population
(Figure 1G) is broken up into smaller LD blocks in the YRI
population (Figure 1H). Differential AE was found in 10 of
36 heterozygous YRI individuals for ORMDL3 and in 21 of
32 heterozygous YRI individuals for GSDMB. Again, maps
of AE-associated SNPs were generated for GSDMB and
ORMDL3 with the phased genotype data available for the
HapMap YRI LCL samples (Figure 1F; Tables S4 and S5).
To account for multiple testing in each locus, permutation
tests (n ¼ 100,000) were carried out and locus-wide empir-
ical signiﬁcances of allelic expression associations forber 11, 2009
Table 1. Allelic Expression-Associated SNPs Found within the 160 kb CEU Haplotype on Chromosome 17
GSDMB CEUa
AE p Value
GSDMB YRIb
AE p Value SNP
Chromosomal
Location
Genic
Location
Overexpressed
CEU Haplotype
FAIRE
Enrichment
Allelic Effect
(un/ov)
1.09 3 1018 4.95 3 107 rs907091 35175268 IKZF3 T þ nt
3.01 3 1012 1.0 rs907092c 35175785 IKZF3 G nt nt
1.09 3 1018 2.39 3 108 rs9303277 35229995 IKZF3 C þþ 1.91
0.0127 1.0 rs2060941 35236409 IKZF3 G þ 0.98
3.60 3 1017 2.39 3 108 rs3816470 35239327 IKZF3 A þ 1.17
3.01 3 1012 0.6651 rs4795397 35277271 intergenic A þþþ 1.61
2.46 3 1006 1.0 rs12150079 35278943 ZPBP2 G þþ 1.17
1.09 3 1018 2.26 3 104 rs11557467 35282160 ZPBP2 G þ 0.91
1.09 3 1018 4.26 3 109 rs12936231 35282646 ZPBP2 Cd þþþ 3.69
3.01 3 1012 0.0017 rs2872507e 35294289 intergenic Gd nt nt
1.09 3 1018 7.54 3 105 rs9901146 35296869 intergenic Gd þ nt
1.09 3 1018 7.54 3 105 rs12950743 35302759 intergenic Td  nt
3.60 3 1017 6.34 3 104 rs7359623 35303115 intergenic Cd þ/ nt
1.09 3 1018 4.26 3 109 rs8067378 35304874 intergenic Ad þ 0.85
1.09 3 1018 0.346 rs2305479 35315743 GSDMB C nt nt
1.09 3 1018 3.77 3 107 rs2290400f 35319766 GSDMB T þ nt
1.09 3 1018 2.26 3 104 rs1008723 35319793 GSDMB G þ nt
1.09 3 1018 0.233 rs869402 35321569 GSDMB C nt nt
1.09 3 1018 3.76 3 103 rs1011082g 35322040 GSDMB G þ nt
1.09 3 1018 0.243 rs7216389h 35323475 GSDMB T þþ 1.21
1.09 3 1018 7.96 3 105 rs7216558g 35323597 GSDMB T þ nt
1.09 3 1018 1.98 3 105 rs9303281 35327572 GSDMB A þ/ nt
1.09 3 1018 7.96 3 105 rs7219923 35328044 GSDMB T þ nt
1.09 3 1018 7.96 3 105 rs7224129 35328952 intergenic A þ nt
7.14 3 1015 1.0 rs4378650h 35334391 ORMDL3 G  nt
6.12 3 1016 0.0058 rs12603332h 35336333 ORMDL3 C þ nt
Allelic effect defined as the ratio of alleles in FAIRE-enriched samples normalized to the ratio of alleles in the input is shown. These values are based on measure-
ments of sequencing chromatograms and indicate the departure from equal ratio.
Abbreviations: nt, not tested; un/ov, underexpressed/overexpressed haplotype; þ/, relative quantity of PCR product visualized on agarose gel.
a Fisher’s exact test p values generated from 32 CEU LCLs.
b Fisher’s exact test p values generated from 21 YRI LCLs.
c Primary biliary cirrhosis-associated SNP.
d 22 kb YRI haplotype.
e Crohn disease-associated SNP.
f Type I diabetes.
g Non-HapMap SNP.
h Asthma-associated SNPs.GSDMB and ORMDL3 by Fisher’s exact test were derived: in
the CEU data set, both genes were associated to AE at
Pperm < 1 3 105, and in the YRI data set, GSDMB was
associated at Pperm < 1 3 105 whereas ORMDL3 did
not reach signiﬁcance (Pperm < 0.5). Overall, the overlap
of the AE-associated SNPs between the CEU and YRI sug-
gested that a SNP(s) common among the two populations
may be the cause of the AE observed.
Haplotype analysis of the YRI GSDMB AE data revealed
a 22 kb segment of the CEU haplotype, bound byThe Americanrs12936231 and rs8067378 (stars in Figure 1F), that is
also associated (p ¼ 4.26 3 109) with higher expression
of GSDMB (Table 1; Table S4). We primarily focused our
efforts to the 22 kb region showing the top associations
in YRI but note that there are additional SNPs that are
strongly associated with AE in the YRI samples as well
(Table 1). In the CEU population, the originally suggested
functional SNP (rs7216389)4 is strongly associated with
AE (p ¼ 1.09 3 1018). However, in the YRI population,
rs7216389 is not in strong LD with AE-associating SNPsJournal of Human Genetics 85, 377–393, September 11, 2009 383
Figure 3. Quantitative Real-Time PCR Results for IKZF3, ZPBP2, GSDMB, and ORMDL3 Performed in 53 CEU LCLs, All Normalized for
18S and Correlated with the Common CEU Overexpressed-Associated Haplotype
‘‘A’’ represents the CEU haplotype associated with the overexpression of GSDMB and ‘‘B’’ is any other haplotype (AA ¼ 9, AB ¼ 32,
BB ¼ 12). Error bars were calculated by the mean5 SD for each genotype.and is not linked to AE (p ¼ 0.243), excluding it as a causal
candidate for the AE observed across populations. The best
functional candidate based on evolutionary sequence
conservation (28-way Vertebrate Multiz alignment)38
among the AE-associated SNPs is rs12936231, which lies
in a conserved 50 bp block, with the G allele being
conserved across mammalian species. None of the other
SNPs with strong AE association observed in both YRI
and CEU (rs8067378, rs9303277, rs3816470, rs2290400,
and rs907091) showed signiﬁcant conservation.
To identify all the possible genetic variants that may
potentially be involved in the regulation of AE, the 160
kb CEU haplotype was tiled with long-range PCR ampli-
cons for four individuals (2 CEU and 2 YRI) carrying the
common AE-associated haplotype and resequenced with
a high-throughput 454 GS-FLX sequencer. Within the
160 kb interval, 13 SNPs previously not genotyped by
HapMap and showing heterozygosity in two of the four
samples with differential AE were considered as candidate
sites. These SNPs were subsequently genotyped in either
our CEU and YRI panels or our YRI panel only, phased
within the sample set, and tested for AE association
(r2 values for these SNPs with rs12936231 can be found
in Table S7). Two of these SNPs (rs1011082 and
rs7216558) were found to be strongly associated with AE
in the CEU population (p ¼ 1.09 3 1018) but not as
strongly in the YRI population (p ¼ 3.76 3 103–7.96 3
105) (Table 1). The sensitivity of our algorithm for
detecting heterozygous SNPs in our samples for known
polymorphisms is 98.5%,19 and our results suggest that
nearly all candidate variants were identiﬁed. However, we
were not able to genotype three SNPs that lay in SINE
repeat elements, and both Sequenom assay and Sanger
sequencing failed. These SNPs were not predicted to be
heterozygous in all sequenced samples, so we note that
they are less likely to be strongly associated with AE (Table
S7). In addition, no heterozygous insertions, deletions, or
copy number variations were detected within the 160 kb
resequenced haplotype or identiﬁed through the Database
of Genomic Variants,20 suggesting that differences in
allele-speciﬁc expression must result from the effect of
a single SNP or the combination of multiple SNPs.384 The American Journal of Human Genetics 85, 377–393, SeptemTo validate the effect of the overexpressed-associated
haplotype on the gene expression of GSDMB, ORMDL3,
ZPBP2, and IKZF3, quantitative real-time PCRs were per-
formed on a panel of 53 CEU LCL samples. As expected,
the expression correlation against the common CEU over-
expressed-associated haplotype (AA ¼ 9, AB ¼ 32, BB ¼ 12,
where A represents the CEU haplotype associated with
overexpression of GSDMB and B is any other haplotype)
showed that individuals that are homozygous for the
overexpressed-associated haplotype (AA) have a signiﬁcant
increase in GSDMB (p ¼ 2.75 3 105) and ORMDL3
(p¼ 0.00388) and lower ZPBP2 (p¼ 0.00371) mRNA levels,
relative to individuals that do not carry the overexpressed-
associated haplotype (BB) (Figure 3). IKZF3 expression was
not correlated with the overexpressed-associated haplo-
type (p ¼ 0.87068).
Identiﬁcation of the Causal cis-Regulatory Variant(s)
Three different approaches were used to assess the func-
tional potential of the AE-associated SNPs: all CEU AE-asso-
ciated SNPs were tested for allele-speciﬁc chromatin differ-
ences in vivo, additionally the top three AE-associated
SNPs (rs12936231, rs9303277, and rs8067378) observed
in both the CEU and YRI populations as well as the original
asthma-associated SNP (rs7216369) were tested for their
regulatory potential and allele-speciﬁc DNA-protein inter-
actions in vitro.
Given that the 17q12 haplotype affects the expression of
multiple transcripts, we hypothesized that genetic varia-
tion in this region might inﬂuence chromatin states and
alter gene regulation in a domain-wide manner. To test
for this possibility, we screened all the SNPs that were
strongly associated with AE in the CEU population to
detect allele-speciﬁc differences in chromatin states with
the formaldehyde-assisted isolation of regulatory elements
(FAIRE) assay combined with PCR and Sanger sequencing.
Like the DNase I hypersensitivity assay, FAIRE detects DNA
regions that are devoid of nucleosomes and that often
contain regulatory elements.22,39 Overall, 16 AE-associated
SNPs, 3 asthma-associated SNPs, and 3 control SNPs were
tested for FAIRE enrichment in at least two heterozygous
cell lines (Table 1). Only two of the SNPs showed highber 11, 2009
Figure 4. Allele-Specific Chromatin Effects in the rs12936231 Region
(A) Sequencing assay to detect allele-speciﬁc FAIRE enrichment andmicrococcal nuclease (MNase) sensitivity. The negative strand of the
rs12936231 region is shown and the position of the SNP is indicated by an arrow.
(B) Genotype effect on FAIRE enrichment for rs12936231, qPCR results on FAIRE-treated LCLs (GG ¼ 4, CG ¼ 7, CC ¼ 3).
(C) Association of the rs12936231 alleles with active and inactive chromatin marks as determined by X-ChIP qPCR assays (GG ¼ 4 and
CC ¼ 4).
(D) Allele-speciﬁc CTCF binding detected by X-ChIP qPCR assay in homozygous GG (n ¼ 4) and CC (n ¼ 4) LCLs.
For (B), (C), and (D), the error bars were calculated with the mean 5 SD for each genotype.
(E) Summary diagram for the allele-speciﬁc chromatin conformation in the rs12936231 region (left) and gene expression (right) in the
ZPBP2-ORMDL3 region.FAIRE enrichment (rs4795397 and rs12936231) denoted as
þþþ in Table 1, but only rs12936231 showed a robust,
allele-speciﬁc FAIRE enrichment in all eight heterozygous
cell lines tested (Figure 4A). The rs12936231 G allele was
consistently overrepresented in the FAIRE-enriched frac-
tion (G/C ratio 3.69). To validate the FAIRE results, the
rs12936231 region was tested for the presence of nucleo-
some-free DNAwithMNase treatment in ﬁve heterozygous
cell lines. This region showed a strong allele-speciﬁc
MNase sensitivity, with the G allele being preferentially
digested by MNase (Figure 4A). The genotype effect ofThe Americanrs12936231 on the FAIRE enrichment was then tested by
quantitative PCR experiments (Figure 4B). LCL samples
homozygous for the C allele consistently showed a low
level of FAIRE enrichment in contrast to the two other
genotypes. Therefore, independent approaches suggest
that the two alleles of the rs12936231 SNP have a different
association with nucleosomes.
The rs12936231 SNP showed in vivo differences in its
chromatin distribution, so follow-up studies were carried
out. Allele-speciﬁc gene expression has been associated
with different modiﬁcations of histone tails on activeJournal of Human Genetics 85, 377–393, September 11, 2009 385
Figure 5. Gene Reporter Assays for Promoter Haplotypes Carrying the rs12936231 Region
Relative luciferase activity of the promoter haplotypes was measured after transient transfection in ﬁve different cell lines. Each haplo-
type was transfected in both sense and antisense and performed in quadruplicates (mean 5 SD). The empty promoterless pGL3-Basic
vector was used as a negative control. **p < 0.01.and silent alleles;23,40,41 therefore, the association of the
rs12936231 region with H3Ac (active chromatin mark)
and H3K9me3 or H3K27me3 (marks of inactive chro-
matin) via native ChIP (N-ChIP) and crosslinking ChIP
(X-ChIP) assays was tested. In this study, the N-ChIP data
provides information about the allele that resists MNase
digestion (i.e., the C allele), whereas the X-ChIP character-
izes both alleles. Both assays showed that the rs12936231
DNA region is associated with active chromatin marks in
homozygous individuals of either genotype (Figure 4C;
Figure S2). Although better enrichment with the active
histone mark H3Ac is found on the G allele, the difference
failed to reach statistical signiﬁcance.
About 70% of ubiquitous distal (R2 kb from the tran-
scriptional start site) DNase I hypersensitive sites are associ-
ated with the CCTC binding protein CTCF.42 Furthermore,
rs12936231 variants alter the sequence of putative binding
sites for CTCF25,43 and p300 (Figure S3). CTCF is a well-
characterized protein involved in chromatin looping and
is known to reposition nucleosomes.44,45 Therefore, we
assayed the allele-speciﬁc association of rs12936231 with
CTCF in LCLs that were homozygous for the G or the
C allele via X-ChIP assays. The results indicate that the G
allele isCTCF enriched compared to theCallele (Figure 4D).
We note that the CTCF binding to this region was recently
independently demonstrated by ENCODE46 ChIP se-
quencing showing LCL-speciﬁc CTCF-ChIP-seq. peak
centered on the rs12936231 SNP (Figure S4).
Converging lines of functional data show that the
rs12936231 explains, in part, the allele-speciﬁc differences
observed in the transcription of ZPBP2, GSDMB, and
ORMDL3. The G allele of the rs12936231, which is associ-
ated with lower GSDMB and ORMDL3 and higher ZPBP2
expression, is mostly devoid of nucleosomes, but associ-
ated with CTCF. In contrast, the C allele, which is associ-
ated with higher ORMDL3 and GSDMB and lower ZPBP2
expression, is not enriched with CTCF.
In parallel with in vivo analyses of expression and chro-
matin activity, we carried out in vitro analyses of candidate
SNPs. The regulatory potential of the three SNPs most
strongly associated with AE (rs9303277, rs12936231, and
rs8067378) as well as rs7216369 was tested by transient386 The American Journal of Human Genetics 85, 377–393, Septemtransfection assays in ﬁve immortalized cell types: cervical
cancer (HeLa), hepatocellular carcinoma (HepG2), chorio-
carcinoma (Jeg3), osteosarcoma (MG-63), and CD4þ T cell
leukemia (Jurkat). Allele-speciﬁc constructs for each SNP
were tested with an SV40 minimal promoter-containing
vector (enhancer activity) and a pGL3 basic vector
(promoter activity). Only the pGL3 construct containing
the rs12936231 showed signiﬁcant allele-speciﬁc differ-
ences in promoter activity (p < 0.01), which was seen in
four cell lines (HeLa, Jeg3, HepG2, MG-63) (Figure 5).
The increase in activity was observed for the G allele but
only when the construct was in an antisense orientation
(when referenced to GSDMB/ORMDL3 orientation). Slight
cell-type-speciﬁc enhancer activity was observed for
rs9303277 and rs12936231 but not in an allele-speciﬁc
manner (all data, including constructs for the GSDMB
and ORMDL3 promoters, can be found on the GRiD
website).
Finally, these same candidate SNPs were also assayed to
determine allele-speciﬁc DNA-protein interactions via elec-
trophoreticmobility shift assays (EMSA) in nuclear extracts
from LCLs. The cell speciﬁcity of the binding was tested in
four additional immortalized cancer cell types: HeLa,
HepG2, Jeg3, and MG-63. Of the four SNPs tested, only
rs8067378 showed allele-speciﬁc differences for DNA-
protein interactions in LCLs (Figure 6). Allele-speciﬁc
differences for rs8067378 in protein binding were also
found in all other cell lines. All EMSA results can be found
in Figure S6.
Functional Haplotype and Risk of Asthma
The relationship of the rs12936231 SNP with asthma
susceptibility has not been previously assessed. Therefore,
we pursued association studies for our top functional candi-
date SNP (rs12936231), three other SNPs (rs8067378,
rs9303277, and rs3816470) occurring in the same CEU
haplotype, and the asthma-associated rs7216389 SNP.4
The association studies were carried out in three indepen-
dent family-based asthma cohorts. All four candidate
AE-associated SNPs demonstrated signiﬁcant evidence for
association (a < 0.03 in individual cohorts,36 p ¼ 8.74 3
107–4.95 3 108 by Fisher combined test) in each of theber 11, 2009
cohorts, and haplotype association analysis conﬁrmed
a strong association of the overexpressed-associated haplo-
type with asthma risk (p¼ 8.623 108; Tables 2 and 3). We
note that despite varying statistical signiﬁcance of the asso-
ciations across cohorts, the observed transmission disequi-
librium levels were similar (transmitted to nontransmitted
ratios for rs12936231 is 1.44 in Costa Rica, 1.27 in CAMP,
and 1.61 in the SLSJ asthmatic familial collection), suggest-
ing that the observed differences in p values are due to
differences in the number of informative families in each
study. The strong LD between these markers in the popula-
tions tested precludes preferential recognition of one
variant over the others as the deﬁnitive risk locus, because
the combined evidence for association was very similar
across markers (Fisher’s combined p values of 4.95 3 108
for rs9303277 and 8.74 3 107 for rs12936231). We note,
however, that the allelic associations at these markers are
slightly stronger than thoseobserved for thepreviously sug-
gested causal variant (rs7216389 Fisher’s combined p value
p ¼ 3.04 3 106).
Figure 6. Positive EMSA Analyses Showing Allelic
DNA-Protein Interactions for SNP rs8067378G>A in LCLs
The unlabeled probes used to complete DNA-protein inter-
actions are indicated (þ) at the top of each lane. Speciﬁc
competitors corresponding to the unlabeled allele-speciﬁc
probes were used in lanes 3, 4, 8, and 9 and a nonspeciﬁc
competitor was used in lanes 5 and 10. The three predom-
inant allele-speciﬁc DNA-protein complexes are indicated
by arrows. All other cell types tested showed similarly
strong allele-speciﬁc effects for this SNP, whereas none of
the other SNPs yielded consistently strong EMSA signals
(Figure S6).
Discussion
Clinical association data for common complex
disease susceptibility often have, as in the case of
the 17q12 associations, relatively modest odds ratio
(OR).4,9–11 This inherently limits the power of a study
in mapping causal variants: small changes in the OR
by closely linked SNPs in LDwould require very large
cohorts. One strategy utilized for strong disease asso-
ciations (e.g., TCF7L2 for type 2 diabetes) is to carry out
mapping in patient cohorts that are genetically more
diverse to exploit population-speciﬁc differences in LD,
which may allow more efﬁcient ﬁne-mapping.47 It has
also been suggested that cellular phenotypes could be
used as a tool for dissecting disease variation.48 So far,
the only functional link of the LD block associated with
asthma and autoimmune diseases has been altered gene
regulation in the 17q12-q21 locus observed in human lym-
phoblastoid cells.4,9,14 Allelic expression, as we have previ-
ously shown for thousands of cis-regulated genes, can
segregate in a Mendelian fashion (B.G., D.K. Pokholok,
T.K., E.G., L. Morcos, D.J.V., J. Le, V.K., K.C.L.L., V. Gagne´,
J.D., R.H., A. Montpetit, M.-M. Joly, E.J. Harvey, D.S., P.
Beaulieu, R. Hamon, A. Graziani, K.D., E.H., J. Majewski,
H.H.H. Go¨ring, A.K.N., M. Blanchette, K.L. Gunderson,
and T.P., unpublished data), and we can demonstrate
transmission of AE phenotypes with the asthma-associated
haplotype (Figure 2; Figure S1). The heritable cis-variants
also largely explain (r2 ¼ 0.97) the population variationTable 2. TDT Results for Polymorphisms Located in the 17q12 Region in Three Asthma Cohorts
SNP
Risk
Allele
Costa Rican Hispanic
CAMP Non-Hispanic
White
SLSJ Asthmatic Familial
Collection (White)
Fisher’s Combined
Test
Trio # T:U c2 p Value Trio # T:U c2 p Value Trio # S:E(S) Z Score p Value c2 p Value
rs9303277 C 275 294:198 18.7 1.50 3 105 444 293:227 8.4 0.004 134 306:278 3.0 0.003 44.9 4.95 3 108
rs3816470 A 261 278:191 16.1 5.89 3 105 412 287:228 6.8 0.009 157 335:312 2.3 0.024 36.4 2.34 3 106
rs12936231 C 278 294:204 16.3 5.51 3 105 449 285:224 7.3 0.007 136 300:276 2.5 0.011 38.6 8.74 3 107
rs8067378 A 280 301:201 19.9 8.07 3 106 436 286:225 7.3 0.007 152 333:308 2.4 0.015 41.8 2.03 3 107
rs7216389 T 382 299:200 19.6 9.32 3 106 278 202:173 2.24 0.130 154 300:276 2.4 0.0146 35.8 3.04 3 106
T:U denotes ratio of transmitted to untransmitted risk alleles; S denotes association test statistic and E(S) is the expected statistic. Fisher’s combined p value calcu-
lated for k number of p values by c2 ¼ 2Ploge(p valuek) with 2k degrees of freedom.The American Journal of Human Genetics 85, 377–393, September 11, 2009 387
T
a
b
le
3
.
H
a
p
lo
ty
p
ic
T
D
T
R
e
su
lt
s
fo
r
th
e
F
o
u
r
S
N
P
H
a
p
lo
ty
p
e
s
L
o
c
a
te
d
in
th
e
1
7
q
1
2
R
e
g
io
n
in
T
w
o
A
st
h
m
a
C
o
h
o
rt
s
H
a
p
lo
ty
p
e
a
C
o
st
a
R
ic
a
n
H
is
p
a
n
ic
C
A
M
P
N
o
n
-H
is
p
a
n
ic
W
h
it
e
S
L
S
J
A
st
h
m
a
ti
c
F
a
m
il
ia
l
C
o
ll
e
c
ti
o
n
,
W
h
it
e
F
is
h
e
r’
s
C
o
m
b
in
e
d
T
e
st
T
ri
o
#
H
a
p
lo
ty
p
e
F
re
q
u
e
n
c
y
T
:U
c
2
p
V
a
lu
e
T
ri
o
#
H
a
p
lo
ty
p
e
F
re
q
u
e
n
c
y
T
:U
c
2
p
V
a
lu
e
T
ri
o
#
H
a
p
lo
ty
p
e
F
re
q
u
e
n
c
y
S
:E
(S
)
Z
S
c
o
re
p
V
a
lu
e
c
2
p
V
a
lu
e
C
:A
:C
:A
2
9
0
0
.5
8
3
0
2
:2
0
1
2
0
.3
6
.6
0
x
1
0

6
3
3
7
0
.5
0
3
5
6
:2
8
4
8
.0
0
.0
0
5
1
8
0
0
.5
8
3
1
7
:2
9
2
2
.6
0
.0
1
0
4
3
.6
8
.6
2
x
1
0

8
T
:G
:G
:G
2
8
7
0
.3
9
1
9
6
:2
9
7
2
0
.5
5
.9
0
X
1
0

6
3
2
6
0
.4
4
2
7
8
:3
4
9
8
.0
0
.0
0
5
1
7
8
0
.3
7
1
9
1
:2
2
1
3
.1
0
.0
0
2
4
7
.1
1
.7
8
x
1
0

8
C
:G
:C
:A
N
/A
N
/A
N
/A
N
/A
5
1
0
.0
3
3
4
:3
0
0
.3
0
.5
7
4
3
0
0
.0
4
2
6
:2
4
0
.6
0
.5
3
8
-
T
:G
:C
:A
N
/A
N
/A
N
/A
N
/A
3
0
0
.0
2
2
1
:1
8
0
.3
0
.5
8
2
N
/A
N
/A
N
/A
N
/A
-
C
:G
:G
:G
4
4
0
.0
2
2
2
:2
6
0
.3
0
.6
1
5
N
/A
N
/A
N
/A
N
/A
N
/A
N
/A
N
/A
N
/A
-
O
m
n
ib
u
s
h
ap
lo
ty
p
e
te
st
b
0
.0
0
2
0
.0
2
0
.0
5
4
2
6
.1
0
.0
0
0
2
T
:U
d
e
n
o
te
s
ra
ti
o
o
f
tr
a
n
sm
it
te
d
to
u
n
tr
a
n
sm
it
te
d
ri
sk
a
lle
le
s;
S
d
e
n
o
te
s
a
ss
o
ci
a
ti
o
n
te
st
st
a
ti
st
ic
a
n
d
E
(S
)
is
th
e
e
x
p
e
ct
e
d
st
a
ti
st
ic
.
D
a
ta
p
re
se
n
te
d
fo
r
h
a
p
lo
ty
p
e
s
p
re
se
n
t
in
R
1
%
o
f
th
e
p
o
p
u
la
ti
o
n
.
Fi
sh
e
r’
s
co
m
b
in
e
d
p
va
lu
e
ca
lc
u
la
te
d
fo
r
k
n
u
m
b
e
r
o
f
p
va
lu
e
s
b
y
c
2
¼
2
P
lo
g
e
(p
va
lu
e
k
)
w
it
h
2
k
d
e
g
re
e
s
o
f
fr
e
e
d
o
m
.
a
rs
9
3
0
3
2
7
7
:r
s3
8
1
6
4
7
0
:r
s1
2
9
3
6
2
3
1
:r
s8
0
6
7
3
7
8
.
b
S
ta
ti
st
ic
im
p
le
m
e
n
te
d
in
P
B
A
T
v3
.6
.388 The American Journal of Human Genetics 85, 377–393, Septein AE in the CEU, and although unidentiﬁed rare variants
may also have an effect on the AE observed, the effect sizes
are predicted to be small. The large effect sizes combined
with interethnic ﬁne-mapping allow us to formulate
speciﬁc hypotheses on the causal cis-regulatory SNPs in
the locus. Although expression and AE phenotypes have
been shown to overlap GWAS hits in multiple earlier
studies, this study is the ﬁrst one to our knowledge with
systematic functional follow-up for pinpointing the causal
variant(s).
We demonstrate that the genetic variants associated
with asthma and autoimmune disease act over a large
genomic region and affect the expression of not one but
several transcripts. We suggest that rs12936231 is part of
a regulatory region that governs the transcriptional
activity of at least three genes (ZPBP2, GSDMB, and
ORMDL3) in the chromosome 17q12-q21 region and that
it is one of the leading functional candidates explaining
the phenotypic association with asthma. A trans-based
expression analysis using the ingenuity pathway analysis
(IPA) of the rs12936231 SNP via public data sets13,37
revealed no reproducible effect on other genes or pathways
(Table S6). The allele-speciﬁc protein-DNA interactions
detected for rs8067378 along with converging AE-
mapping results in the two populations may be a modiﬁer
of cis-regulation.We note that although functional SNPs in
the 22 kb shared haplotype provide the best parsimonious
explanation for heritable variation in gene regulation in
both population at the 17q12-q21 locus, it is clear that
either local haplotype (other cis-acting SNPs) or trans-
acting differences between the populations may modulate
this effect, as indicated by the fact that the ORMDL3 asso-
ciation in the YRI is signiﬁcantly weaker and the magni-
tude of the AE in GSDMB is larger in the CEU. To reﬁne
our understanding of the underlying molecular mecha-
nism, further work, such as isolation of the differentially
binding proteins at the rs12936231 and rs8067378
regions, mapping of the chromatin loops and in vivo
validation of our hypotheses using large insert (i.e., BAC)
reporter gene constructs in transgenic mice are called for.
Typical of clinical association data, the resolution of
mapping in this strong LD region does not allow dissection
of the effect of an individual SNP on asthma risk. This is not
unexpected given the odds ratio reported for asthma associ-
ation (<1.5),4whichwould require thousands of samples in
a resequencing study to detect causal variant among closely
linked SNPs (M.S., J. Chicoine, D. Serre, T.P., and R. Sladek,
unpublished simulation studies). On the other hand, the
allelic expression trait at GSDMB is almost completely
explained by the associated SNPs, and the large effect size
renders ﬁne-mapping of the cellular trait feasible even in
small sample sizes, as expected.49 Nevertheless, the best
functional SNPs delineated in this study could clearly
explain the asthma association as well as show strong LD
with CD-, T1D-, and PBC-associated variants.9–11 If the
causal SNPs exert population independent risks for these
traits, an interethnic ﬁne-mapping strategy could furthermber 11, 2009
resolve the issue of marginal effects explained by SNPs
versus haplotypic effects.
The effect of genetic variation, including SNPs, on the
transcription of multiple genes residing in the same chro-
mosomal domain has been documented in sheep, mice,
and humans (B.G., D.K. Pokholok, T.K., E.G., L. Morcos,
D.J.V., J. Le, V.K., K.C.L.L., V. Gagne´, J.D., R.H., A. Montpe-
tit, M.-M. Joly, E.J. Harvey, D.S., P. Beaulieu, R. Hamon, A.
Graziani, K.D., E.H., J. Majewski, H.H.H. Go¨ring, A.K.N.,
M. Blanchette, K.L. Gunderson, and T.P., unpublished
data50–52 and reviewed in 53), and its role in determining
epigenetic states has also been demonstrated in genome-
wide studies.54 Our work provides another example of
the inﬂuence of a common genetic variant on chromatin
states and, to our knowledge, is the ﬁrst report of a SNP
that affects nucleosome positioning and CTCF binding in
cis and that is also linked to common complex trait suscep-
tibility in humans.
CTCF is the only known insulator protein in mammals
(reviewed in 55,56). Its binding to insulator DNA elements
may block enhancers from activating their target genes
via formation of chromatin loops, thereby limiting the
enhancer activity to a certain chromosomal domain and
deﬁne nuclear architecture (reviewed in 45,55).56 Unlike
enhancer elements, the function of insulator sequences
depends upon orientation57 and in some instances insula-
torsmay also act as decoypromoters (reviewed in 55). There-
fore, the promoter activity of the rs12926231 region that
was detected in the in vitro transfection assays may be
part of its insulator features. Alternatively, it may reﬂect
the presence of a polymorphic binding site for a transcrip-
tional activator, such as the E1A binding protein p300
(Figure S3). Based on our data, we hypothesize that the G
and C alleles of rs12936231 contribute to alternative
conformations of the chromosome17q12-q21, the asthma-
associated haplotype (bearing the C allele of rs12936231)
favoring 2- to 4-fold higher expression of GSDMB and
ORMDL3 and 2-fold lower expression of ZPBP2 than
the other common haplotype (Figure 4E). Genome-wide
studies of CTCF binding in different cell lines (ﬁbroblasts,58
CD4þ T cells, Jurkat, and HeLa cells59) have provided cell-
type-speciﬁcmaps of CTCF binding sites within theZPBP2/
GSDMB/ORMDL3 domain. Interestingly, rs12936231 is
located within a region of weak CTCF binding in the
CD4þ T cells (chr17:35282380-35282673).59 In addition,
newly released Broad Chip-seq ENCODE data for CTCF
revealed a binding site at the rs12936231 SNP in a heterozy-
gous LCL sample (GM12878) (Figure S4).46 Although this
region is not signiﬁcantly associated with CTCF in
other cell types, this may reﬂect the genotype speciﬁcity
of CTCF binding at the rs12936231 SNP. The role of
rs8067378, which also has suggestive functional data, is
less clear. It may be part of a transcriptional regulatory
element and/or involved in deﬁning the architecture of
chromatin loops in this domain. Our proposedmechanism
is reminiscent of modiﬁed chromatin looping in the 4q35
region resulting fromD4Z4 deletions in patientswith facio-The Americanscapulohumeral dystrophy.60,61 An important observation
for the 17q12-q21 region is that changes in gene expression
levels are subtle, which is consistent with probabilistic
effects of mutations inﬂuencing epigenetic states.53,62 It is
also possible that both chromatin conformations coexist
in the cell population and environmental triggersmay shift
the equilibrium in favor of one of the conformations.
Our results suggest that the role of the 17q12-q21 chro-
mosomal region in the predisposition to asthma may
result from changes in expression of one of the genes in
this chromosomal domain or a combined effect of changes
in expression of all three transcripts. This same region was
among the validated GWA hits for three autoimmune
diseases: CD,9 T1D,10 and PBC.11 The top SNPs for this
region are rs2872507 for CD, rs2290400 for T1D, and
rs907092 for PBC, all of which are also associated with
AE in CEU LCLs (p ¼ 3.01 3 1012, p ¼ 1.09 3 1018,
and p ¼ 3.01 3 1012, respectively; Table 1). In contrast
to the alleles implicated in the predisposition to asthma,
the CD, T1D, and PBC risk alleles are found on the haplo-
type associated with decreased expression of GSDMB
and ORMDL3. All the associated diseases are, in part, char-
acterized by an abnormal inﬂammatory response, and
because the allelic transcriptional effects were detected in
cells of lymphoid origin, we speculate that the haplotype
harboring rs12936231 and controlling gene expression
in the 17q12-q21 region may have a general impact on
inﬂammation. The gene product of GSDMB is an inter-
esting candidate for the etiology of asthma and autoim-
mune disease. GSDMB is a 411 amino acid protein that is
part of the gasdermin family, which is believed to play a
role as a metabolic product involved in a secretory path-
way and may also be involved in achieving and maintain-
ing the ﬁnal differentiation state of epithelial cells.63,64
Transcriptional and translational regulation of these alter-
natively spliced isoforms has been seen in the develop-
ment and/or progression of gastrointestinal and hepatic
cancers.63 GSDMB is highly expressed in T cells (CD8þ Tc
and CD4þ Th) and moderately expressed in fetal lung,
but it has low expression in bronchial epithelial cells.65
However, the pleiotropic effect of the closely linked SNPs
on multiple diseases could suggest a more direct role on
the control of immune system function rather than func-
tion in any speciﬁc target cell type. In parallel, with the
opposite effects of the 17q12 haplotypes on the risk of
developing asthma versus autoimmune disease, there is
evidence of Th1 versus Th2 cell type inﬂammatory
response predominance in allergic versus autoimmune
disease66 warranting further studies of the potential regula-
tory role ofGSDMB or other transcripts in the region. Inter-
estingly, genotype-controlled expression of GSDMB is also
observed in RNA panels derived from brain cortex and
from peripheral blood mononuclear cells67 but not in
osteoblasts (Figure S7), indicating that the allele-speciﬁc
regulation observed, although tissue speciﬁc, is not re-
stricted to EBV-transformed B cells. We note that a substan-
tial proportion (>30%) of cis-variants discovered inJournal of Human Genetics 85, 377–393, September 11, 2009 389
immortalized LCLs are shared in primary cells of distinct
lineage12 (B.G., D.K. Pokholok, T.K., E.G., L. Morcos,
D.J.V., J. Le, V.K., K.C.L.L., V. Gagne´, J.D., R.H., A. Montpe-
tit, M.-M. Joly, E.J. Harvey, D.S., P. Beaulieu, R. Hamon, A.
Graziani, K.D., E.H., J. Majewski, H.H.H. Go¨ring, A.K.N.,
M. Blanchette, K.L. Gunderson, and T.P., unpublished
data) similar to rates observed between different human
tissues.68 Furthermore, given the inﬂuence of 17q12 region
in multiple inﬂammatory/autoimmune traits, we believe
that the lymphoid lineage represented by the LCL tran-
scriptome is also directly relevant to these types of diseases.
In more general terms, our study highlights the chal-
lenges of dissecting the function of noncoding variants,
where gene expression or chromatin changes observed
in vivomay not be replicated by existing in vitro tools.69,70
Our approach was to use the AE genetic association data as
the primary tool for prioritization of SNPs for further
studies. It is remarkable that two completely independent
allele-speciﬁc approaches in living cells converged to impli-
cate rs12926231 as a key functional variant in the disease-
associated haplotype. At the same time, the strongly
positive EMSA results for rs8067378, which showed an
equally strong link with AE, cannot be overlooked since at
present, the rates of false negative results in chromatin
assays in living cells are unknown.
In conclusion, we have presented a systematic approach
for dissecting common regulatory variation in disease-
linked haplotypes. This approach allowed us to uncover
a domain-wide genetic cis-regulatory effect that is likely
to result from genotype-dependent DNA-protein interac-
tions, nucleosomes positioning, and CTCF binding. Our
data brings us a step closer to elucidating the mechanism
for genetic susceptibility to a common disease. This work
demonstrates the power of model systems and cellular
phenotypes to isolate causal noncoding variants, and
more generally, highlights the diversity of tools and
converging lines of evidence needed for characterization
of noncoding disease variation.
Supplemental Data
Supplemental Data include seven ﬁgures and seven tables and can
be found with this article online at http://www.ajhg.org/.
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